{"id":38262,"date":"2024-07-16T13:37:12","date_gmt":"2024-07-16T13:37:12","guid":{"rendered":"https:\/\/silly-shirley.82-223-1-47.plesk.page\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/"},"modified":"2024-07-16T13:37:12","modified_gmt":"2024-07-16T13:37:12","slug":"un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama","status":"publish","type":"post","link":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/","title":{"rendered":"Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama"},"content":{"rendered":"

Un estudi promogut per SOLTI i publicat a Nature Communications descriu la biologia del tumor associada a l’activitat del f\u00e0rmac patritumab deruxtec\u00e0n, un antic\u00f2s conjugat a quimioter\u00e0pia, en pacients amb c\u00e0ncer de mama preco\u00e7.<\/p>\n

Demostra que la baixa expressi\u00f3 d’HER2, juntament amb la informaci\u00f3 obtinguda de signatures gen\u00e8tiques complexes, es correlacionen amb una major activitat del f\u00e0rmac. Aix\u00ed, la integraci\u00f3 de dades biol\u00f2giques emergeix com un predictor potent per determinar si el f\u00e0rmac ser\u00e0 m\u00e9s o menys efectiu en cada pacient.<\/p>","protected":false},"excerpt":{"rendered":"

Un estudi promogut per SOLTI i publicat a Nature Communications descriu la biologia del tumor associada a l’activitat del f\u00e0rmac patritumab deruxtec\u00e0n, un antic\u00f2s conjugat a quimioter\u00e0pia, en pacients amb c\u00e0ncer de mama preco\u00e7. Demostra que la baixa expressi\u00f3 d’HER2, juntament amb la informaci\u00f3 obtinguda de signatures gen\u00e8tiques complexes, es correlacionen amb una major activitat<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"tipo":[],"class_list":{"0":"post-38262","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-uncategorized"},"acf":[],"yoast_head":"\nUn biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama - Recerca en salut<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama - Recerca en salut\" \/>\n<meta property=\"og:description\" content=\"Un estudi promogut per SOLTI i publicat a Nature Communications descriu la biologia del tumor associada a l’activitat del f\u00e0rmac patritumab deruxtec\u00e0n, un antic\u00f2s conjugat a quimioter\u00e0pia, en pacients amb c\u00e0ncer de mama preco\u00e7. Demostra que la baixa expressi\u00f3 d’HER2, juntament amb la informaci\u00f3 obtinguda de signatures gen\u00e8tiques complexes, es correlacionen amb una major activitat\" \/>\n<meta property=\"og:url\" content=\"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/\" \/>\n<meta property=\"og:site_name\" content=\"Recerca en salut\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-16T13:37:12+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/07\\\/16\\\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/07\\\/16\\\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama\",\"datePublished\":\"2024-07-16T13:37:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/07\\\/16\\\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\\\/\"},\"wordCount\":112,\"commentCount\":0,\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/07\\\/16\\\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/07\\\/16\\\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\\\/\",\"url\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/07\\\/16\\\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\\\/\",\"name\":\"Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama - Recerca en salut\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/#website\"},\"datePublished\":\"2024-07-16T13:37:12+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/07\\\/16\\\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/07\\\/16\\\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/07\\\/16\\\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/#website\",\"url\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/\",\"name\":\"Recerca en salut\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama - Recerca en salut","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/","og_locale":"es_ES","og_type":"article","og_title":"Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama - Recerca en salut","og_description":"Un estudi promogut per SOLTI i publicat a Nature Communications descriu la biologia del tumor associada a l’activitat del f\u00e0rmac patritumab deruxtec\u00e0n, un antic\u00f2s conjugat a quimioter\u00e0pia, en pacients amb c\u00e0ncer de mama preco\u00e7. Demostra que la baixa expressi\u00f3 d’HER2, juntament amb la informaci\u00f3 obtinguda de signatures gen\u00e8tiques complexes, es correlacionen amb una major activitat","og_url":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/","og_site_name":"Recerca en salut","article_published_time":"2024-07-16T13:37:12+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/#article","isPartOf":{"@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/"},"author":{"name":"","@id":""},"headline":"Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama","datePublished":"2024-07-16T13:37:12+00:00","mainEntityOfPage":{"@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/"},"wordCount":112,"commentCount":0,"articleSection":["Uncategorized"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/","url":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/","name":"Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama - Recerca en salut","isPartOf":{"@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/#website"},"datePublished":"2024-07-16T13:37:12+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/07\/16\/un-biomarcador-ajuda-a-seleccionar-les-pacients-que-responen-millor-al-patritumab-deruxtecan-en-cancer-de-mama\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/diarisanitat.cat\/recerca-en-salut\/"},{"@type":"ListItem","position":2,"name":"Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtec\u00e0n en c\u00e0ncer de mama"}]},{"@type":"WebSite","@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/#website","url":"https:\/\/diarisanitat.cat\/recerca-en-salut\/","name":"Recerca en salut","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/diarisanitat.cat\/recerca-en-salut\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/posts\/38262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/comments?post=38262"}],"version-history":[{"count":0,"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/posts\/38262\/revisions"}],"wp:attachment":[{"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/media?parent=38262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/categories?post=38262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/tags?post=38262"},{"taxonomy":"tipo","embeddable":true,"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/tipo?post=38262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}